PapersPMID:32232984
Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- meta-analysis
What moved
How to read these marks →“Meta-analysis of data from twelve randomized controlled trials showed that lactoferrin supplementation to enteral feeds decreased late-onset sepsis (typical RR 0.82, 95% CI 0.74 to 0.91; typical RD -0.04, 95% CI, -0.06, -0.02; NNTB 25, 95% CI 17 to 50; 12 studies, 5425 participants, low-certainty evidence) and decreased length of hospital stay (MD -2.38, 95% CI, -4.67, -0.09; 3 studies, 1079 participants, low-certainty evidence).”
- Decreases hospital length of stay
very limited
- Participants
- 1,079
- Effect
- −2.38 mean difference, 95% CI −4.67 to −0.09
- Population
- preterm neonates in hospital, lactoferrin added to enteral feeds; length of stay to discharge (3 trials pooled)
- Decreases late-onset sepsis incidence (neonatal)
very limitedreplicated ×2
- Participants
- 5,425
- Effect
- 0.82 risk ratio, 95% CI 0.74 to 0.91
- Population
- preterm neonates in randomised and quasi-randomised trials of lactoferrin added to enteral feeds (12 trials pooled)
Study record
- Design
- meta-analysis
- Species
- human / none
- Population
- Preterm neonates in randomized controlled trials of enteral lactoferrin supplementation, alone or with probiotics (Cochrane review); lactoferrin source not stated in abstract; abstract only
- Participants
- not reported
- Comparator
- not stated in the paper / placebo
- Duration
- not reported
- Endpoints measured
- 21